Table 1.
Summary of the long‐term follow up of patients enrolled in the phase I study
| Patient no. by cohort | Sex | Age (years) | Disease | Overall response to mogamulizumab | PFS (days) | OS (days) | Rash (grade) |
|---|---|---|---|---|---|---|---|
| 1 | |||||||
| 101 | M | 46 | MF tumor stage | PD | 29 | 1166+ | 2 |
| 102 | M | 60 | ATL acute | SD→CRa | 2830+ | 2830+ | None |
| 103 | F | 68 | ATL acute | PR | 85 | 732 | None |
| 2 | |||||||
| 201 | M | 55 | ATL acute | SD | 50+ | 230 | None |
| 202 | F | 66 | ATL acute | SD | 36 | 201 | None |
| 203 | M | 66 | ATL acute | PD | 8+ | 61 | None |
| 204 | F | 57 | ATL acute | CR | 1268 | 2447 | None |
| 3 | |||||||
| 301 | M | 60 | ATL acute | PD | 36 | 298 | None |
| 302 | M | 64 | ATL acute | PD | 29 | 270 | None |
| 303 | F | 69 | ATL lymphoma | PD | 29 | 260 | None |
| 4 | |||||||
| 401 | F | 64 | PTCL‐NOS | PR | 2507+ | 2507+ | 2 |
| 402 | F | 62 | ATL acute | PR | 64 | 207 | None |
| 403 | F | 64 | ATL lymphoma | SD | 43 | 1103 | None |
| Expanded | |||||||
| 411 | M | 55 | ATL acute | PD | 28 | 506 | None |
| 412 | M | 62 | ATL acute | CR | 506 | 2048+ | 3 |
| 413 | F | 58 | PTCL‐NOS | SD | 1272 | 2230+ | 2 |
a
Disease had disappeared by 1 year after treatment; patient 102 was categorized as showing a CR. ATL, adult T‐cell leukemia‐lymphoma; CR, complete response; MF, mycosis fungoides; OS, overall survival; PD, progressive disease; PFS, progression‐free survival; PR, partial response; PTCL‐NOS, peripheral T‐cell lymphoma, not otherwise specified; SD, stable disease.